The effect of fecal microbiota transplantation on antibiotic-associated diarrhea and its impact on gut microbiota.
Antibiotic-associated diarrhea
Dysbiosis
Efficacy
Fecal microbiota transplantation
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
received:
29
11
2023
accepted:
14
03
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
9
5
2024
Statut:
epublish
Résumé
Antibiotic-associated diarrhea (AAD) refers to symptoms of diarrhea that cannot be explained by other causes after the use of antibiotics. AAD is thought to be caused by a disruption of intestinal ecology due to antibiotics. Fecal Microbiota Transplantation (FMT) is a treatment method that involves transferring microbial communities from the feces of healthy individuals into the patient's gut. We selected 23 AAD patients who received FMT treatment in our department. Before FMT, we documented patients' bowel movement frequency, abdominal symptoms, routine blood tests, and inflammatory markers, and collected fecal samples for 16S rRNA sequencing to observe changes in the intestinal microbiota. Patients' treatment outcomes were followed up 1 month and 3 months after FMT. Out of the 23 AAD patients, 19 showed a clinical response to FMT with alleviation of abdominal symptoms. Among them, 82.61% (19/23) experienced relief from diarrhea, 65% (13/20) from abdominal pain, 77.78% (14/18) from abdominal distension, and 57.14% (4/7) from bloody stools within 1 month after FMT. Inflammatory markers IL-8 and CRP significantly decreased after FMT, but there were no noticeable changes in WBC, IL-6, and TNF-α before and after transplantation. After FMT, the abundance of Bacteroides and Faecalibacterium increased in patients' fecal samples, while the abundance of Escherichia-Shigella and Veillonella decreased. FMT has a certain therapeutic effect on AAD, and can alleviate abdominal symptoms and change the intestinal microbiota of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Antibiotic-associated diarrhea (AAD) refers to symptoms of diarrhea that cannot be explained by other causes after the use of antibiotics. AAD is thought to be caused by a disruption of intestinal ecology due to antibiotics. Fecal Microbiota Transplantation (FMT) is a treatment method that involves transferring microbial communities from the feces of healthy individuals into the patient's gut.
METHOD
METHODS
We selected 23 AAD patients who received FMT treatment in our department. Before FMT, we documented patients' bowel movement frequency, abdominal symptoms, routine blood tests, and inflammatory markers, and collected fecal samples for 16S rRNA sequencing to observe changes in the intestinal microbiota. Patients' treatment outcomes were followed up 1 month and 3 months after FMT.
RESULTS
RESULTS
Out of the 23 AAD patients, 19 showed a clinical response to FMT with alleviation of abdominal symptoms. Among them, 82.61% (19/23) experienced relief from diarrhea, 65% (13/20) from abdominal pain, 77.78% (14/18) from abdominal distension, and 57.14% (4/7) from bloody stools within 1 month after FMT. Inflammatory markers IL-8 and CRP significantly decreased after FMT, but there were no noticeable changes in WBC, IL-6, and TNF-α before and after transplantation. After FMT, the abundance of Bacteroides and Faecalibacterium increased in patients' fecal samples, while the abundance of Escherichia-Shigella and Veillonella decreased.
CONCLUSION
CONCLUSIONS
FMT has a certain therapeutic effect on AAD, and can alleviate abdominal symptoms and change the intestinal microbiota of patients.
Identifiants
pubmed: 38724904
doi: 10.1186/s12866-024-03261-0
pii: 10.1186/s12866-024-03261-0
doi:
Substances chimiques
Anti-Bacterial Agents
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
160Informations de copyright
© 2024. The Author(s).
Références
Liao W, Chen C, Wen T, et al. Probiotics for the prevention of antibiotic-associated diarrhea in adults: a Meta-analysis of randomized placebo-controlled trials. J Clin Gastroenterol. 2021;55(6):469–80.
doi: 10.1097/MCG.0000000000001464
pubmed: 33234881
Lukasik J, Dierikx T, Besseling-van der Vaart I, et al. Multispecies probiotic for the prevention of antibiotic-associated diarrhea in children: a randomized clinical trial. JAMA Pediatr. 2022;176(9):860–6.
doi: 10.1001/jamapediatrics.2022.1973
pubmed: 35727573
pmcid: 9214631
McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–78.
doi: 10.2217/17460913.3.5.563
pubmed: 18811240
Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol. 2004;42(3):1203–6.
doi: 10.1128/JCM.42.3.1203-1206.2004
pubmed: 15004076
pmcid: 356823
Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334–9.
doi: 10.1056/NEJMcp011603
pubmed: 11821511
Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis. 2001;7(2):136–45.
doi: 10.1097/00054725-200105000-00010
pubmed: 11383587
Högenauer C, Hammer HF, Krejs GJ, et al. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998;27(4):702–10.
doi: 10.1086/514958
pubmed: 9798020
Cummings JH, Pomare EW, Branch WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28(10):1221–7.
doi: 10.1136/gut.28.10.1221
pubmed: 3678950
pmcid: 1433442
Scheppach W, Müller JG, Boxberger F, et al. Histological changes in the colonic mucosa following irrigation with short-chain fatty acids. Eur J Gastroenterol Hepatol. 1997;9(2):163–8.
doi: 10.1097/00042737-199702000-00010
pubmed: 9058627
Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81(3):1031–64.
doi: 10.1152/physrev.2001.81.3.1031
pubmed: 11427691
Hill C, Guarner F, Reid G, et al. Expert consensus document. The international scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14.
doi: 10.1038/nrgastro.2014.66
pubmed: 24912386
Vindigni SM, Surawicz CM. Fecal microbiota transplantation. Gastroenterol Clin North Am. 2017;46(1):171–85.
doi: 10.1016/j.gtc.2016.09.012
pubmed: 28164849
Dai M, Liu Y, Chen W, et al. Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients. Crit Care. 2019;23(1):324.
doi: 10.1186/s13054-019-2604-5
pubmed: 31639033
pmcid: 6805332
Danne C, Rolhion N, Sokol H. Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nat Rev Gastroenterol Hepatol. 2021;18(7):503–13.
doi: 10.1038/s41575-021-00441-5
pubmed: 33907321
van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15.
doi: 10.1056/NEJMoa1205037
pubmed: 23323867
Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal microbiota transplantation is superior to Fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019;156(5):1324–1332.e1323.
doi: 10.1053/j.gastro.2018.12.019
pubmed: 30610862
Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835–43.
doi: 10.1111/apt.13144
pubmed: 25728808
Cui J, Lin Z, Tian H, et al. Long-term follow-up results of fecal microbiota transplantation for irritable bowel syndrome: a single-center. Retros Study Front Med. 2021;8:710452.
doi: 10.3389/fmed.2021.710452
Tian H, Ge X, Nie Y, et al. Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. PloS One. 2017;12(2):e0171308.
doi: 10.1371/journal.pone.0171308
pubmed: 28158276
pmcid: 5291446
Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2[J]. Nat Biotechnol. 2019;37(8):852–7.
doi: 10.1038/s41587-019-0209-9
pubmed: 31341288
pmcid: 7015180
Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–3.
doi: 10.1038/nmeth.3869
pubmed: 27214047
pmcid: 4927377
Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.
doi: 10.1186/gb-2011-12-6-r60
pubmed: 21702898
pmcid: 3218848
Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020;38(6):685–8.
doi: 10.1038/s41587-020-0548-6
pubmed: 32483366
pmcid: 7365738
Kanehisa M, Goto S, Sato Y, et al. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40(Database issue):D109–14.
doi: 10.1093/nar/gkr988
pubmed: 22080510
Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
doi: 10.1093/nar/28.1.27
pubmed: 10592173
pmcid: 102409
Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51.
doi: 10.1002/pro.3715
pubmed: 31441146
pmcid: 6798127
Kanehisa M, Furumichi M, Sato Y, et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–d592.
doi: 10.1093/nar/gkac963
pubmed: 36300620
El-Salhy M, Hatlebakk JG, Gilja OH, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859–67.
doi: 10.1136/gutjnl-2019-319630
pubmed: 31852769
El-Salhy M, Winkel R, Casen C, et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 2022;163(4):982–994.e914.
doi: 10.1053/j.gastro.2022.06.020
pubmed: 35709830
Wei S, Bahl MI, Baunwall SMD, et al. Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection. Gut Microbes. 2022;14(1):2084306.
doi: 10.1080/19490976.2022.2084306
pubmed: 36519447
pmcid: 9176232
Li Q, Ding X, Liu K, et al. Fecal microbiota transplantation for ulcerative colitis: the optimum timing and gut microbiota as predictors for long-term clinical outcomes. Clin Transl Gastroenterol. 2020;11(8):e00224.
doi: 10.14309/ctg.0000000000000224
pubmed: 32955197
pmcid: 7431231
van den Bogert B, Meijerink M, Zoetendal EG, et al. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota. PloS One. 2014;9(12):e114277.
doi: 10.1371/journal.pone.0114277
pubmed: 25479553
pmcid: 4257559
Goeser F, Münch P, Lesker TR, et al. Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity? Gut. 2021;70(2):438–40.
pubmed: 32503844
Paramsothy S, Nielsen S, Kamm MA, et al. Specific Bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology. 2019;156(5):1440–1454.e1442.
doi: 10.1053/j.gastro.2018.12.001
pubmed: 30529583
Kaakoush NO. Sutterella species, IgA-degrading Bacteria in ulcerative colitis. Trends Microbiol. 2020;28(7):519–22.
doi: 10.1016/j.tim.2020.02.018
pubmed: 32544438
Lv W, Liu C, Ye C, et al. Structural modulation of gut microbiota during alleviation of antibiotic-associated diarrhea with herbal formula. Int J Biol Macromol. 2017;105(Pt 3):1622–9.
doi: 10.1016/j.ijbiomac.2017.02.060
pubmed: 28219687
Sokol H, Landman C, Seksik P, et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome. 2020;8(1):12.
doi: 10.1186/s40168-020-0792-5
pubmed: 32014035
pmcid: 6998149
Holvoet T, Joossens M, Wang J, et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2017;66(5):980–2.
doi: 10.1136/gutjnl-2016-312513
pubmed: 27511198